DXCM vs RCUS · P/E 63, rev $2.50B vs rev $58.0M
DexCom Inc (DXCM) versus Arcus Biosciences Inc (RCUS) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Arcus Biosciences Inc (RCUS) is a biotechnology company listed on US.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported RCUS revenue for 2026-06-30 was $58.0M. Net income was -$219.0M. RCUS currently screens at market cap $885.2M.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. RCUS currently screens at market cap $885.2M.
Not investment advice. Open the DXCM and RCUS stock pages for the full models.
Not investment advice.